Breast cancer screening: past, present and future

Abstract

Future OncologyVol. 11, No. 19 EditorialBreast cancer screening: past, present and futureIsmail JatoiIsmail Jatoi*Author for correspondence: E-mail Address: jatoi@uthscsa.edu Division of Surgical Oncology & Endocrine Surgery, University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7738, San Antonio, TX 78229, USASearch for more papers by this authorPublished Online:4 Sep 2015https://doi.org/10.2217/fon.15.209AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: mammographymortalityoverdiagnosisscreeningtherapyReferences1 Jatoi I, Anderson WF. Cancer screening. Curr. Probl. Surg. 42(9), 620–682 (2005).Crossref, Medline, Google Scholar2 Force USPST. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 151(10), 716–726 (2009).Crossref, Medline, Google Scholar3 Lauby-Secretan B, Scoccianti C, Loomis D et al. Breast-cancer screening – viewpoint of the IARC Working Group. N. Engl. J. Med. 372(24), 2353–2358 (2015).Crossref, Medline, CAS, Google Scholar4 Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. J. Natl Cancer Inst. 69(2), 349–355 (1982).Medline, CAS, Google Scholar5 Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, g366 (2014).Crossref, Medline, Google Scholar6 Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol. doi:10.1016/S1470-2045(15)00128-X (2015) (Epub ahead of print).Crossref, Medline, Google Scholar7 Jatoi I. The impact of advances in treatment on the efficacy of mammography screening. Prev. Med. 53(3), 103–104 (2011).Crossref, Medline, Google Scholar8 Jatoi I, Miller AB. Why is breast-cancer mortality declining? Lancet Oncol. 4(4), 251–254 (2003).Crossref, Medline, Google Scholar9 Holloway CM, Easson A, Escallon J et al. Technology as a force for improved diagnosis and treatment of breast disease. Can. J. Surg. 53(4), 268–277 (2010).Medline, Google Scholar10 Jatoi I, Anderson WF. Breast cancer overdiagnosis with screening mammography. Arch. Intern. Med. 169(10), 999–1000 (2009).Medline, Google Scholar11 Jatoi I. Breast cancer screening. Am. J. Surg. 177(6), 518–524 (1999).Crossref, Medline, CAS, Google Scholar12 Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J. Natl Cancer Inst. 94(3), 167–173 (2002).Crossref, Medline, Google Scholar13 Miller AB, Yurgalevitch S, Weissfeld JL, Prostate LC, Ovarian Cancer Screening Trial Project T. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin. Trials. 21(6 Suppl.), S400–S406 (2000).Crossref, Google Scholar14 Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N. Engl. J. Med. 367(21), 1998–2005 (2012).Crossref, Medline, CAS, Google Scholar15 Jatoi I. Screening clinical breast examination. Surg. Clin. North Am. 83(4), 789–801 (2003).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited BySurgical management of the axilla in early breast cancerCurrent Problems in Surgery, Vol. 55, No. 2Targeting breast cancer outcomes-what about the primary relatives?31 May 2017 | Molecular Genetics & Genomic Medicine, Vol. 5, No. 4Future Oncology: a 10-year anniversary issueNicholas J Ward & Gemma Westcott7 October 2015 | Future Oncology, Vol. 11, No. 19 Vol. 11, No. 19 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 117 times History Published online 4 September 2015 Published in print October 2015 Information© Future Medicine LtdKeywordsmammographymortalityoverdiagnosisscreeningtherapyFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download